Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q2- Text added to 2020 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
ANJESO, Aspen, asthma, Baudax, Bio, Biopharma, CalciMedica, Canadian, CarT, centralized, Cerecor, channel, CMML, coordinated, CRAC, Crohn, EEA, eosinophilic, epinephrine, Europe, gimsilumab, GvHD, Humanigen, hydrochloride, implant, inhibitor, Innocoll, Lenzilumab, lowest, mab, Mallinckrodt, OFIRMEV, organizational, outplacement, Pfizer, Pharmacare, posing, postsurgical, purpose, reorganization, rulemaking, Secretary, SENSORCAINE, simply, VEKLURY, Xaracoll
Removed:
authorisation, Centralised, Chairman, chief, constituting, Hospira, MAA
Valuein 2020 Q2 filing- Value in 2020 Q3 filing
Original filings
Filing view